SEC Tracker
Get the app

Repligen RGEN

Repligen Q1 FY25: net income $5.8M, up 77%; diluted EPS $0.10

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Repligen reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income$5.8M+77% from $3.3M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS$0.10+67% from $0.06 in Q1 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$697.2M−11% from $780.6M in Q1 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations$15.0M−66% from $44.7M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025